Masood Faghih Dinevari

Masood Faghih Dinevari

Auto-generated profile, based on publicly available information

Masood Faghih Dinevari

Liver and Gastrointestinal Diseases Research Center Tabriz University of Medical Sciences Tabriz Iran

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2023 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
MDMasood Faghih Dinevari
Masood Faghih Dinevari
FJFarzaneh Jafarzadeh
Farzaneh Jafarzadeh
ASAmirreza Jabbaripour Sarmadian
Amirreza Jabbaripour Sarmadian
SASamaneh Abbasian
Samaneh Abbasian
ZNZeinab Nikniaz
Zeinab Nikniaz
ARAli Riazi
Ali Riazi
Background: Irritable bowel syndrome (IBS) is one of the world's most common gastrointestinal (GI) disorders, and current treatments do not meet patients' demands. This study aimed to investigate melatonin's therapeutic effects on IBS score, GI symptoms, quality of life, and sleep parameters in both groups of IBS patients with and without sleep disorders. Methods: In this randomized double-blinded placebo-controlled trial study, 136 patients with a diagnosis of IBS based on ROME IV criteria were enrolled and then divided into two groups respecting having sleep disorders or not. Patients of each group were randomized in a 1:1 ratio to receive melatonin 6 mg daily (3 mg fasting and 3 mg at bedtime) for 2 months (8 weeks). Blocked randomization was used in this process. All patients were evaluated both at the beginning and the end of the trial regarding IBS score, GI symptoms, quality of life, and sleep parameters through valid questionnaires. Results: In both groups of patients with and without sleep disorders, a significant improvement was observed in IBS score and GI symptoms, including the severity and the frequency of abdominal pain, the severity of abdominal bloating, satisfaction with bowel habits, disease's impact on patient's life, and stool consistency; however, there was no significant improvement in the frequency of defecations per week. In patients with sleep disorders, significant improvement in sleep parameters, including subjective sleep quality, sleep latency, sleep duration, sleep efficiency, and daytime dysfunction, was observed, while in patients without sleep disorders, there was no significant improvement in sleep parameters. In addition, quality-of-life improvement was observed in a significant number of melatonin recipients compared to placebo in both groups of patients. Conclusion: Melatonin can be considered an effective treatment for improving IBS score, GI symptoms, and quality of life in IBS patients with and without sleep disorders. It is also effective to improve sleep parameters in IBS patients with sleep disorders. Trial registration: This study has been registered to the Iranian Registry of Clinical Trials (IRCT) with the approval number IRCT20220104053626N2 on the date of 13/02/2022.

15 April 2025 in Traditional & Kampo Medicine
Verified
Journal Article
Closed access
MDMasoud Faghieh Dinavari
Masoud Faghieh Dinavari
HNHossein Nazemiyeh
Hossein Nazemiyeh
MSMohammad Hossein Somi
Mohammad Hossein Somi
ASAmirreza Jabbaripour Sarmadian
Amirreza Jabbaripour Sarmadian
ARAli Riazi
Ali Riazi
FAFatemeh Javanali Azar
Fatemeh Javanali Azar

24 April 2023 in Clinical Case Reports
Verified
Journal Article
Open access
MDMasood Faghih Dinevari
Masood Faghih Dinevari
AEAmirtaher Eftekharsadat
Amirtaher Eftekharsadat
MTMahdi Tarverdizadeh
Mahdi Tarverdizadeh
SRSeyyed Mahdi Rasulimanesh
Seyyed Mahdi Rasulimanesh
ARAli Riazi
Ali Riazi
SASamaneh Abbasian
Samaneh Abbasian
Key Clinical Message: Patients complaining of rectal bleeding, constipation, and a suspicious mass in colonoscopy should undergo biopsy. Histological features such as fibromuscular obliteration in the lamina propria favor SRUS, a benign disorder.

22 February 2023 in Journal of Research in Clinical Medicine
Verified
Journal Article
Open access
PDF file
MDMasood Faghieh Dinevari
Masood Faghieh Dinevari
SASamaneh Abbasian
Samaneh Abbasian
MHMasoud Hejazi
Masoud Hejazi
ARAli Riazi
Ali Riazi
Introduction: The coronavirus disease 20149 (COVID-19) may be associated with the elevated liver enzymes including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), in which the disease has been associated with more severity. Liver stiffness (LS) is associated with the increased liver enzymes. Liver elastography is a non-invasive technique that is used to evaluate LS. This study aimed to evaluate the functional status of liver and its relationship with liver elastography results in the patients with COVID-19. Methods: In this cross-sectional study, 90 patients with COVID-19, whose diagnosis was confirmed by polymerase chain reaction (PCR) test, were included. Levels of liver enzymes were measured and the patients underwent liver elastography. Liver size and interquartile range-median (IQR/M) of LS were also measured. Six months later, the patients underwent another liver elastography and measurement of liver enzymes. Results: The frequency of fatty liver in the case group was significantly higher compared to the control group but no significant difference was observed in the frequency of liver fibrosis between two groups. In patients with COVID-19, the LS and IQR/M values at the beginning and six months after recovery were significantly higher in the group with the increased liver enzymes (case) compared to the group without the increased enzymes (control). P value was 0.001. Conclusion: The use of elastography to evaluate LS in the patients with COVID-19 can be significantly effective in assessing the status of liver damage and inflammation of liver tissue. Since elastography is an inexpensive and non-invasive available tool, it can be used mainly in most medical centers.

13 June 2023 in Clinical Case Reports
Verified
Journal Article
Open access
ARAli Riazi
Ali Riazi
MDMasood Faghih Dinevari
Masood Faghih Dinevari
SASamaneh Abbasian
Samaneh Abbasian
ASAmirreza Jabbaripour Sarmadian
Amirreza Jabbaripour Sarmadian
Key Clinical Message: In patients with acute symptoms such as pain, swelling, and erythema of the upper extremities shortly after receiving COVID‐19 vaccines, even inactivated virus vaccines, these symptoms may indicate thrombosis, which may be due to the vaccination. BBIBP‐CorV COVID‐19 vaccine (Sinopharm vaccine) is an inactivated whole virus vaccine to control the COVID‐19 pandemic. Studies concluded that inactivated COVID‐19 vaccines do not increase the risk of thrombosis. This report presents a 23‐year‐old man with the chief complaint of severe pain, swelling, and erythema of the right upper extremity following his second dose of the Sinopharm vaccine. Duplex ultrasound of the right upper extremity revealed upper extremity deep vein thrombosis, and treatment started with oral anticoagulation. It is probably the first upper extremity deep vein thrombosis case following inactivated COVID‐19 vaccines.

16 October 2024 in Journal of Research in Clinical Medicine
Verified
Journal Article
Open access
PDF file
MDMasood Faghih Dinevari
Masood Faghih Dinevari
MSMohammad Hossein Somi
Mohammad Hossein Somi
LMLeila Mokhtari
Leila Mokhtari
EMElham Sadeghi Majd
Elham Sadeghi Majd
ZNZeinab Nikniaz
Zeinab Nikniaz
Introduction: The prevalence of noncommunicable diseases is high in Iran. We postulated that multimorbidity may affect the rate of mortality from COVID-19. So, we investigated the relationship between multimorbidity and COVID-19 mortality. Methods: We used medical reports for collecting clinical laboratory data of patients with COVID-19 in this prospective investigation. Moreover, we documented whether the patient had a known diagnosis of different comorbidities. The patients with more than one comorbidity were considered multimorbidity. The length of follow-up was till participants were discharged from the hospital or deceased. The main outcome was to evaluate the relationship between multimorbidity and death in COVID-19 hospitalized patients. Results: The present prospective study included 1842 patients with COVID-19 with a multimorbidity rate of 37.40%. About 24.6% of participants with more than four comorbidities died. However, this value was about 17% in participants with less than four comorbidities. The odds of mortality from COVID-19 were 53% greater in patients with diabetes. Also, the odds of death were 2.05 (1.21, 3.45) times greater in patients with comorbidities≥4. Conclusion: The results indicated a high rate of multimorbidity in patients with COVID-19 which is related to a higher death rate. So, in countries with higher multimorbidity rates such as Iran, it is necessary to design efficient approaches to alleviate the spread of COVID-19.